Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT03835533 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: NKTR-214 (Cohort A)
DRUG: Nivolumab (Cohort A, B and C)
RADIATION: Stereotactic body radiation therapy (SBRT) (Cohort B)
DRUG: CDX-301 (Cohort B and C)
DRUG: Poly-ICLC (Cohort B)
DRUG: INO-5151 (Cohort C)
DEVICE: Cellectra 2000

Sponsor

Parker Institute for Cancer Immunotherapy

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]